3 days ago
- Business
- Fashion Value Chain
Supriya Lifescience Q1 FY26 Revenue at Rs 145 Cr
Supriya Lifescience Ltd., a cGMP-compliant API manufacturer with a presence in over 86 countries, has announced its unaudited Q1 FY26 financial results. The company operates across multiple therapeutic categories, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic segments.
Consolidated Financial Results (Q1 FY26 vs Q1 FY25):
Revenue: Rs 145.07 crore, down 9.7% YoY (vs Rs 160.63 crore)
EBITDA: Rs 51.7 crore (vs Rs 62.54 crore)
EBITDA Margin: 35.6% (vs 38.9%)
PAT: Rs 34.79 crore (vs Rs 44.64 crore)
PAT Margin: 24.0% (vs 27.8%)
Quarterly EPS: Rs 4.3 (vs Rs 5.5)
Operational Highlights:
Anaesthetic segment drove revenue, contributing 53% vs 45% in Q1 FY25.
European markets' share rose to 41% from 34% last year.
Capacity utilisation improved to 76% in FY26 from 70% in FY25.
Acquired three land parcels near existing plants to support future growth.
Management Comment:
Mr. Satish Wagh, Chairman and Managing Director, stated, 'Our Q1 results reflect temporary impact from necessary repairs at the Lote facility to enhance efficiency and support new product launches. Despite revenue decline, margins stayed robust at 36% owing to backward integration and stronger regulated market contributions. With the Ambernath site nearing commercialisation in Q4, 3–4 new product launches in FY26, and sustained demand across key therapeutic areas, we anticipate recovery in H2 and remain confident of achieving ~20% growth and Rs 1,000 crore revenue by FY27.'
Supriya Lifescience continues to strengthen its API portfolio with expansion plans, capacity enhancements, and a focus on regulated markets.
